Survey of oncologists finds knowledge gap on medical marijuana
As more states legalize medical marijuana, two key groups — researchers whose job is it to understand its benefits and drawbacks, and physicians charged with advising potential users — are struggling to catch up with policymakers.
Ilana Braun, an assistant professor of psychiatry at Harvard Medical School and chief of the division of adult psychosocial oncology at the Dana-Farber Cancer Institute, led a survey of cancer physicians around the country, exploring their attitudes and actions on medical marijuana.
The survey was sent to 400 oncologists, with a 63 percent response rate. We asked Braun to outline her findings, which were published last month in the Journal of Clinical Oncology.
Stories you may be interested in
Study on cannabis chemical as a treatment for pancreatic cancer may have ‘major impact,’ Harvard researcher says
Pancreatic cancer makes up just 3 percent of all cancers in America. But with a one-year survival rate of just 20 percent (and five-year survival rate of less than 8), it’s predicted to be the second leading cause of cancer-related death by 2020. Headlines about the illness, as a result, tend to be discouraging. But this month scientists from Harvard University’s Dana-Farber…
Read More 
Thanks to the Farm Bill, Hemp Is Legal. Here’s What It Means for CBD.
On Tuesday, the Senate voted to approve a new an $867 billion farm bill, and on Wednesday, it passed in Congress. While the bill has plenty of positive merits, the one people are perhaps most excited about is the fact that it will legalize the production, sale, and distribution of industrial hemp at a federal…
Read More 
IBD and Cannabinoid Medicine
With an estimated 3.1 million adults diagnosed with Irritable Bowel Disease (IBD) in the United States, it’s natural that many people are asking about the possible benefits of cannabis for the symptoms associated with IBD. In fact, the University of Michigan Health Department received so many questions regarding this issue, that they released a Q&A…
Read More 
Research shows cannabis can lower opioid dosage, but studies are preliminary
Larson cited one statistic to justify his bill: “Studies have shown up to 75% reduction in opioid dosage for medical cannabis users” The intersection of medical cannabis and opioid use as treatments for chronic pain is an emerging field of research as more states loosen regulations on medical and recreational use of marijuana. But does…
Read More 
REGISTRATION NOW OPEN: Arfinn Med Medical Cannabis Efficacy Portal for Licensed Medical Professionals
Arfinn Med, the first clinician-based medical professional and patient efficacy portal for medical cannabis treatments, is now open for registrations from licensed medical professionals. The free collaborative portal allows medical professionals to register, share, research and communicate HIPAA-compliant benchmark data for medical cannabis treatments. As a free tool for physicians, Arfinn Med offers a new…
Read More 
Unstructured EHR data more useful for predictive analytics, study shows
A new report in the Journal of the American Medical Informatics Association has shown that real-world data contained in unstructured narratives has big predictive value when it comes to clinical research. WHY IT MATTERSWhile structured clinical notes in the electronic health record have obvious value, the research in JAMIA suggests that real-world data captured in unstructured notes…
Read More